BRPI0513511A - derivados de benzotiazol - Google Patents
derivados de benzotiazolInfo
- Publication number
- BRPI0513511A BRPI0513511A BRPI0513511-7A BRPI0513511A BRPI0513511A BR PI0513511 A BRPI0513511 A BR PI0513511A BR PI0513511 A BRPI0513511 A BR PI0513511A BR PI0513511 A BRPI0513511 A BR PI0513511A
- Authority
- BR
- Brazil
- Prior art keywords
- sup
- sub
- lower alkyl
- disease
- diyl
- Prior art date
Links
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical class C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- -1 3H-imidazole-2,4-diyl Chemical group 0.000 abstract 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 3
- 239000001961 anticonvulsive agent Substances 0.000 abstract 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000011117 substance-related disease Diseases 0.000 abstract 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 abstract 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- 206010010904 Convulsion Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 206010021143 Hypoxia Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 229940025084 amphetamine Drugs 0.000 abstract 1
- 230000003556 anti-epileptic effect Effects 0.000 abstract 1
- 229940125681 anticonvulsant agent Drugs 0.000 abstract 1
- 229960003965 antiepileptics Drugs 0.000 abstract 1
- 239000000164 antipsychotic agent Substances 0.000 abstract 1
- 229940005529 antipsychotics Drugs 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 229930003827 cannabinoid Natural products 0.000 abstract 1
- 239000003557 cannabinoid Substances 0.000 abstract 1
- 229940065144 cannabinoids Drugs 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229960003920 cocaine Drugs 0.000 abstract 1
- 208000029078 coronary artery disease Diseases 0.000 abstract 1
- 230000006735 deficit Effects 0.000 abstract 1
- 206010013663 drug dependence Diseases 0.000 abstract 1
- 229960004756 ethanol Drugs 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 230000007954 hypoxia Effects 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 229940035363 muscle relaxants Drugs 0.000 abstract 1
- 239000003158 myorelaxant agent Substances 0.000 abstract 1
- 230000004112 neuroprotection Effects 0.000 abstract 1
- 229960002715 nicotine Drugs 0.000 abstract 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 229940005483 opioid analgesics Drugs 0.000 abstract 1
- 230000036407 pain Effects 0.000 abstract 1
- 230000029058 respiratory gaseous exchange Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 229940125723 sedative agent Drugs 0.000 abstract 1
- 239000000932 sedative agent Substances 0.000 abstract 1
- 201000009032 substance abuse Diseases 0.000 abstract 1
- 231100000736 substance abuse Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
DERIVADOS DE BENZOTIAZOL. A presente invenção refere-se a compostos de fórmulas gerais IA ou IB: em que: - R¬ 1¬, R¬ 2¬, independentemente entre si, representam alquila inferior ou -(CH~ 2~)~ m~-O-alquila inferior ou formam juntos com o átomo de nitrogênio ao qual se encontram ligados um anel heterocíclico; - R¬ 3¬ representa hidrogênio ou alquila inferior; - R¬ 4¬ representa alquila inferior; - het-arila é 3H-imidazol-2,4-diíla ou 1H-pirazol-1,4-diíla; - n é 1 ou 2, e -m é 1 ou 2; - e a sais de adição ácidos farmaceuticamente aceitáveis dos mesmos. Esses compostos podem ser usados no tratamento de doença de Alzheimer, doença de Parkinson, doença de Huntington, neuroproteção, esquizofrenia, ansiedade, dor, deficiência respiratória, depressão, ADHD, vício em drogas, tais como, anfetamina, cocaína, opióides, álcool, nicotina, canabinóides ou no tratamento de asma, respostas alérgicas, hipoxia, isquemia, convulsão e vício em substâncias químicas ou para uso como sedativos, relaxantes musculares, antipsicóticos, antiepilépticos, anticonvulsivos e agentes cardioprotetores para doenças de artéria coronária e deficiência cardíaca.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04103514 | 2004-07-22 | ||
| PCT/EP2005/007592 WO2006008041A1 (en) | 2004-07-22 | 2005-07-13 | Benzothiazole derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0513511A true BRPI0513511A (pt) | 2008-05-06 |
Family
ID=35124499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0513511-7A BRPI0513511A (pt) | 2004-07-22 | 2005-07-13 | derivados de benzotiazol |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7371749B2 (pt) |
| EP (1) | EP1773827B1 (pt) |
| JP (1) | JP5202946B2 (pt) |
| CN (1) | CN1989139B (pt) |
| AT (1) | ATE457986T1 (pt) |
| AU (1) | AU2005263500B2 (pt) |
| BR (1) | BRPI0513511A (pt) |
| CA (1) | CA2574193C (pt) |
| DE (1) | DE602005019408D1 (pt) |
| ES (1) | ES2339867T3 (pt) |
| MX (1) | MX2007000638A (pt) |
| RU (1) | RU2382782C2 (pt) |
| SG (1) | SG140605A1 (pt) |
| WO (1) | WO2006008041A1 (pt) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE521512C2 (sv) | 2001-06-25 | 2003-11-11 | Niconovum Ab | Anordning för administrering av en substans till främre delen av en individs munhåla |
| EP1578422B1 (en) | 2002-12-20 | 2007-04-11 | NicoNovum AB | A physically and chemically stable nicotine and micorcrystalline cellulose containing particulate material |
| US9402809B2 (en) | 2006-03-16 | 2016-08-02 | Niconovum Usa, Inc. | Snuff composition |
| JP2019514893A (ja) | 2016-04-25 | 2019-06-06 | バイエル・クロップサイエンス・アクチェンゲゼルシャフト | 有害生物防除剤としての置換２−アルキルイミダゾリル−カルボキサミド類 |
| WO2019025099A1 (en) | 2017-08-01 | 2019-02-07 | Merck Patent Gmbh | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS |
| KR20200043433A (ko) | 2017-08-21 | 2020-04-27 | 메르크 파텐트 게엠베하 | 아데노신 수용체 길항제로서의 벤즈이미다졸 유도체 |
| KR20200043434A (ko) | 2017-08-21 | 2020-04-27 | 메르크 파텐트 게엠베하 | 아데노신 수용체 길항제로서의 퀴녹살린 유도체 |
| EP3870294A1 (en) | 2018-10-25 | 2021-09-01 | Merck Patent GmbH | 5-azaindazole derivatives as adenosine receptor antagonists |
| KR20210083287A (ko) | 2018-10-25 | 2021-07-06 | 메르크 파텐트 게엠베하 | 아데노신 수용체 안타고니스트로서의 5-아자인다졸 유도체 |
| AR117844A1 (es) | 2019-01-22 | 2021-09-01 | Merck Patent Gmbh | Derivados de tiazolopiridina como antagonistas del receptor de adenosina |
| DE102019110904B4 (de) | 2019-04-26 | 2022-01-20 | Helmholtz-Zentrum Dresden - Rossendorf E. V. | N-(4-methoxy-7-morpholinobenzo[d]thiazol-2-yl)-acetamid-Derivate und deren Verwendung |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL90337A0 (en) * | 1988-05-24 | 1989-12-15 | Pfizer | Aromatic and heterocyclic carboxamide derivatives as antineoplastic agents |
| RU2251419C2 (ru) * | 2000-06-21 | 2005-05-10 | Ф. Хоффманн-Ля Рош Аг | Производные бензотиазола |
| US6620811B2 (en) * | 2001-11-19 | 2003-09-16 | Hoffmann-La Roche Inc. | Isonicotin- and nicotinamide derivatives of benzothiazoles |
| US6599901B1 (en) * | 2001-11-19 | 2003-07-29 | Hoffman-La Roche Inc. | Pyridone substituted benzothiazole derivatives |
| US6624163B2 (en) * | 2001-11-29 | 2003-09-23 | Hoffman-La Roche Inc. | Benzothiazole derivatives |
| US6727247B2 (en) * | 2001-12-10 | 2004-04-27 | Hoffman-La Roche Inc. | Substituted benzothiazole amide derivatives |
| US6713499B2 (en) * | 2001-12-12 | 2004-03-30 | Hoffman-La Roche Inc. | 7-Amino-benzothiazole derivatives |
-
2005
- 2005-07-13 AU AU2005263500A patent/AU2005263500B2/en not_active Ceased
- 2005-07-13 BR BRPI0513511-7A patent/BRPI0513511A/pt not_active Application Discontinuation
- 2005-07-13 CN CN2005800242052A patent/CN1989139B/zh not_active Expired - Fee Related
- 2005-07-13 WO PCT/EP2005/007592 patent/WO2006008041A1/en not_active Ceased
- 2005-07-13 MX MX2007000638A patent/MX2007000638A/es active IP Right Grant
- 2005-07-13 EP EP05771937A patent/EP1773827B1/en not_active Expired - Lifetime
- 2005-07-13 ES ES05771937T patent/ES2339867T3/es not_active Expired - Lifetime
- 2005-07-13 RU RU2007101052/04A patent/RU2382782C2/ru not_active IP Right Cessation
- 2005-07-13 SG SG200801488-8A patent/SG140605A1/en unknown
- 2005-07-13 CA CA2574193A patent/CA2574193C/en not_active Expired - Fee Related
- 2005-07-13 DE DE602005019408T patent/DE602005019408D1/de not_active Expired - Lifetime
- 2005-07-13 JP JP2007521857A patent/JP5202946B2/ja not_active Expired - Fee Related
- 2005-07-13 AT AT05771937T patent/ATE457986T1/de active
- 2005-07-18 US US11/183,503 patent/US7371749B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DE602005019408D1 (de) | 2010-04-01 |
| EP1773827B1 (en) | 2010-02-17 |
| MX2007000638A (es) | 2007-03-07 |
| RU2382782C2 (ru) | 2010-02-27 |
| JP2008506736A (ja) | 2008-03-06 |
| US20060019949A1 (en) | 2006-01-26 |
| CA2574193A1 (en) | 2006-01-26 |
| CN1989139B (zh) | 2010-05-12 |
| AU2005263500A1 (en) | 2006-01-26 |
| JP5202946B2 (ja) | 2013-06-05 |
| CN1989139A (zh) | 2007-06-27 |
| ATE457986T1 (de) | 2010-03-15 |
| RU2007101052A (ru) | 2008-08-27 |
| WO2006008041A1 (en) | 2006-01-26 |
| EP1773827A1 (en) | 2007-04-18 |
| AU2005263500B2 (en) | 2011-02-24 |
| US7371749B2 (en) | 2008-05-13 |
| CA2574193C (en) | 2013-03-05 |
| ES2339867T3 (es) | 2010-05-26 |
| SG140605A1 (en) | 2008-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP088863A (es) | Compuestos que son agonistas de receptores muscarínicos y que pueden ser eficaces en el tratamiento del dolor, la enfermedad de alzheimer y/o la esquizofrenia | |
| ATE457986T1 (de) | Benzothiazolderivate | |
| WO2001097786A3 (en) | Benzothiazole derivatives | |
| MXPA04004683A (es) | Derivados de benzotiazoles tal como ligandos de receptores de adenosina. | |
| NZ537341A (en) | Quinuclidine amide derivatives as antimuscarinic agents to treat respiratory disorders | |
| CY1108104T1 (el) | (4-μεθοξυ-7-μορφολιν-4-υλο-βενζοθειαζολ-2-υλο) αμιδιο του 4-υδροξυ-4-μεθυλο-πιπεριδινο-1-καρβοξυλικου οξεος | |
| TW200508180A (en) | Therapeutic agents | |
| SE0104334D0 (sv) | Therapeutic agents | |
| JP2013531008A5 (pt) | ||
| PE20081755A1 (es) | Nuevas 2-aminooxazolinas como ligandos taar1 | |
| BRPI0414266A (pt) | derivados de tiazolopiridina como ligandos receptores da adenosina | |
| NO20085271L (no) | Muscarin reseptoragonister som er effektive i behandling av smerte, Alzheimers sykdom og schizofreni | |
| PE20071224A1 (es) | Derivados de aminometilpiridina como antagonistas de los receptores cannabinoides 1 (cb1) | |
| US20020094986A1 (en) | Combination treatment for depression, anxiety and psychosis | |
| UA92327C2 (ru) | Применение n-арилдиазаспироциклических соединений для лечения зависимостей | |
| MX2007004250A (es) | Derivados de imidazo[1,5-a]triazolo[1,5-d]benzodiazepina para el tratamiento de trastornos cognitivos. | |
| TW200608970A (en) | Substituted benzothiazoles | |
| AR037457A1 (es) | Compuestos derivados de benzotiazol, su empleo, un procedimiento para prepararlos y medicamentos que los contienen | |
| AR037792A1 (es) | Compuestos derivados de benzotiazol, su uso, un procedimiento para su obtencion y medicamentos que los contienen | |
| PE20081664A1 (es) | Derivados de azabicicloalcano, su preparacion y su aplicacion en terapeutica | |
| DE60203106D1 (de) | Azolylcarbynol-derivative von aryl (oder heteroaryl) zur behandlung von atemwegserkrankungen | |
| JO2502B1 (en) | 4-Hydroxy-4-methyl-piperidine-1-carboxylic acid-4) methoxy-7-morpholine-4-yl-benzothiazole-2-yl) -amide | |
| WO2006071603A3 (en) | Phosphodiesterase 4d in the ryanodine receptor complex protects against heart failure | |
| AR037791A1 (es) | Compuestos derivados de benzotiofeno, su empleo, un procedimiento para prepararlos y medicamentos que los contienen | |
| AU2008258664A8 (en) | Prolinamide-tetrazole derivatives as NK3 receptor antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL |